Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy

Area of Science:

• Oncology
• Immunology
• Cardiology

Background:

• Immune checkpoint inhibitors (ICIs) are revolutionizing cancer therapy but can trigger immune-related adverse events (irAEs).
• Cardiovascular irAEs, particularly autoimmune myocarditis, represent a significant clinical challenge.
• Existing guidelines for anticancer drug cardiovascular effects contrast with the lack of specific protocols for ICI-induced irAEs.

Purpose of the Study:

• To highlight the spectrum and severity of cardiovascular irAEs associated with immune checkpoint blockade.
• To underscore the critical need for diagnostic guidelines for ICI-related cardiovascular events.
• To emphasize the potential underestimation of myocarditis prevalence and the importance of case studies.

Main Methods:

• Review of existing literature and databases (e.g., WHO database) on ICI-associated cardiovascular irAEs.
• Analysis of documented cases to understand clinical presentation, outcomes, and potential prevalence.
• Comparative analysis with guidelines for other cardiotoxic anticancer agents.

Main Results:

• Autoimmune myocarditis is the most characterized cardiovascular irAE, with reported mortality rates ranging from 36% to 67%.
• Cardiovascular irAEs can lead to rapid and fatal clinical deterioration.
• Recent studies suggest autoimmune myocarditis may be more prevalent than previously thought.

Conclusions:

• There is an urgent need for standardized guidelines for identifying and managing ICI-related cardiovascular irAEs.
• Improved case identification and understanding are crucial for better patient outcomes.
• The potential severity and possible underestimation of these events necessitate further research and clinical vigilance.